Impact Analysis of Covid-19
The complete version of the REPORT will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.
In this report, the United States Oncology Biosimilars market is valued at USD XX million in 2019 and is expected to reach USD XX million by the end of 2025, growing at a CAGR of XX% between 2019 and 2025.
Geographically, this report splits the United States market into seven regions:
The West
Southwest
The Middle Atlantic
New England
The South
The Midwest
with sales (volume), revenue (value), market share and growth rate of Oncology Biosimilars in these regions, from 2018 to 2025 (forecast).
United States Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including
Celltrion Inc.
Pfizer Inc.
Biocon
BIOCAD
Apotex Inc.
Dr. Reddy's Laboratories Ltd.
Sandoz International GmbH
Intas Pharmaceuticals Ltd.
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into
G-CSF
Hematopoietic Agents
Monoclonal Antibodies
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Oncology Biosimilars for each application, including
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
United States Oncology Biosimilars Market Report 2019
1 Oncology Biosimilars Overview
1.1 Product Overview and Scope of Oncology Biosimilars
1.2 Classification of Oncology Biosimilars by Product Category
1.2.1 United States Oncology Biosimilars Market Size (Sales Volume) Comparison by Type (2014-2024)
1.2.2 United States Oncology Biosimilars Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 G-CSF
1.2.4 Hematopoietic Agents
1.2.5 Monoclonal Antibodies
1.3 United States Oncology Biosimilars Market by Application/End Users
1.3.1 United States Oncology Biosimilars Market Size (Consumption) and Market Share Comparison by Application (2014-2024)
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 United States Oncology Biosimilars Market by Region
1.4.1 United States Oncology Biosimilars Market Size (Value) Comparison by Region (2014-2024)
1.4.2 The West Oncology Biosimilars Status and Prospect (2014-2024)
1.4.3 Southwest Oncology Biosimilars Status and Prospect (2014-2024)
1.4.4 The Middle Atlantic Oncology Biosimilars Status and Prospect (2014-2024)
1.4.5 New England Oncology Biosimilars Status and Prospect (2014-2024)
1.4.6 The South Oncology Biosimilars Status and Prospect (2014-2024)
1.4.7 The Midwest Oncology Biosimilars Status and Prospect (2014-2024)
1.5 United States Market Size (Value and Volume) of Oncology Biosimilars (2014-2024)
1.5.1 United States Oncology Biosimilars Sales and Growth Rate (2014-2024)
1.5.2 United States Oncology Biosimilars Revenue and Growth Rate (2014-2024)
2 United States Oncology Biosimilars Market Competition by Players/Suppliers
2.1 United States Oncology Biosimilars Sales and Market Share of Key Players/Suppliers (2014-2019)
2.2 United States Oncology Biosimilars Revenue and Share by Players/Suppliers (2014-2019)
2.3 United States Oncology Biosimilars Average Price by Players/Suppliers (2014-2019)
2.4 United States Oncology Biosimilars Market Competitive Situation and Trends
2.4.1 United States Oncology Biosimilars Market Concentration Rate
2.4.2 United States Oncology Biosimilars Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Oncology Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
3 United States Oncology Biosimilars Sales (Volume) and Revenue (Value) by Region (2014-2019)
3.1 United States Oncology Biosimilars Sales and Market Share by Region (2014-2019)
3.2 United States Oncology Biosimilars Revenue and Market Share by Region (2014-2019)
3.3 United States Oncology Biosimilars Price by Region (2014-2019)
4 United States Oncology Biosimilars Sales (Volume) and Revenue (Value) by Type (Product Category) (2014-2019)
4.1 United States Oncology Biosimilars Sales and Market Share by Type (Product Category) (2014-2019)
4.2 United States Oncology Biosimilars Revenue and Market Share by Type (2014-2019)
4.3 United States Oncology Biosimilars Price by Type (2014-2019)
4.4 United States Oncology Biosimilars Sales Growth Rate by Type (2014-2019)
5 United States Oncology Biosimilars Sales (Volume) by Application (2014-2019)
5.1 United States Oncology Biosimilars Sales and Market Share by Application (2014-2019)
5.2 United States Oncology Biosimilars Sales Growth Rate by Application (2014-2019)
5.3 Market Drivers and Opportunities
6 United States Oncology Biosimilars Players/Suppliers Profiles and Sales Data
6.1 Celltrion Inc.
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Oncology Biosimilars Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Celltrion Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.1.4 Main Business/Business Overview
6.2 Pfizer Inc.
6.2.2 Oncology Biosimilars Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Pfizer Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.2.4 Main Business/Business Overview
6.3 Biocon
6.3.2 Oncology Biosimilars Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Biocon Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.3.4 Main Business/Business Overview
6.4 BIOCAD
6.4.2 Oncology Biosimilars Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 BIOCAD Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.4.4 Main Business/Business Overview
6.5 Apotex Inc.
6.5.2 Oncology Biosimilars Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Apotex Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.5.4 Main Business/Business Overview
6.6 Dr. Reddy's Laboratories Ltd.
6.6.2 Oncology Biosimilars Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.6.4 Main Business/Business Overview
6.7 Sandoz International GmbH
6.7.2 Oncology Biosimilars Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Sandoz International GmbH Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.7.4 Main Business/Business Overview
6.8 Intas Pharmaceuticals Ltd.
6.8.2 Oncology Biosimilars Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.8.4 Main Business/Business Overview
6.9 STADA Arzneimittel AG
6.9.2 Oncology Biosimilars Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.9.4 Main Business/Business Overview
6.10 Teva Pharmaceutical Industries Ltd.
6.10.2 Oncology Biosimilars Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2014-2019)
6.10.4 Main Business/Business Overview
7 Oncology Biosimilars Manufacturing Cost Analysis
7.1 Oncology Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Oncology Biosimilars
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Oncology Biosimilars Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Oncology Biosimilars Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Oncology Biosimilars Market Size (Value and Volume) Forecast (2019-2024)
11.1 United States Oncology Biosimilars Sales Volume, Revenue Forecast (2019-2024)
11.2 United States Oncology Biosimilars Sales Volume Forecast by Type (2019-2024)
11.3 United States Oncology Biosimilars Sales Volume Forecast by Application (2019-2024)
11.4 United States Oncology Biosimilars Sales Volume Forecast by Region (2019-2024)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
